179 results
8-K
EX-99.1
NUWE
Nuwellis Inc
7 May 24
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
11:02am
received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking
8-K
EX-99.2
NUWE
Nuwellis Inc
30 Apr 24
Nuwellis Announces Pricing of $2.7 Million Public Offering
6:25pm
an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking
8-K
EX-99.1
NUWE
Nuwellis Inc
30 Apr 24
Nuwellis Announces Pricing of $2.7 Million Public Offering
6:25pm
provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies
424B4
NUWE
Nuwellis Inc
29 Apr 24
Prospectus supplement with pricing info
4:58pm
and training materials, to constitute promotion of an uncleared, uncertified or unapproved use of a medical device. In the U.S., engaging
8-K
lt821d9
26 Mar 24
Other Events
5:00pm
8-K
EX-99.1
qj9cc7nde4 qjrmla31
6 Mar 24
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
12:02pm
8-K
EX-99.1
3r3bpb0lpg3uv pot
7 Nov 23
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
8:15am
8-K
EX-99.1
xy9zspb4f chp0vzca
1 Nov 23
Nuwellis Announces Board of Directors Transition
4:15pm
8-K
EX-99.1
ih8srq7xv77eo3f20
17 Oct 23
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
4:30pm
8-K
EX-99.2
37s60jt6nw0um3thjpr
17 Oct 23
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
4:30pm
424B4
kbyet
13 Oct 23
Prospectus supplement with pricing info
6:16pm
8-K
EX-99.1
8z2ns7iyh20l fu9pr
10 Oct 23
Other Events
8:30am
POS AM
wqfal5e5ye6
4 Oct 23
Prospectus update (post-effective amendment)
5:29pm